Join a Treatment Study

This is a Phase 3 clinical trial of CM-AT, pancreatic enzyme, in patients aged 9–12 years with autistic disorder. It is hoped that CM-AT will help improve autistic symptoms through a positive impact on gastrointestinal function.

The purpose of this trial is to evaluate the efficacy and safety of two fixed doses of lurasidone (20 mg/day and 60 mg/day) for 6 weeks compared with placebo in pediatric and adolescent subjects with irritability associated with autistic disorder who reside in the community setting.

This multi-center, randomized, double-blind, parallel group, placebo-controlled, proof of concept study will investigate the efficacy and safety of RG7314, a vasopressin 1a (V1a) receptor antagonist, in adult patients with autism spectrum disorders.

The study is a 12-week, open-label trial examining the tolerability of Vitamin D replacement in children with autism spectrum disorders. The study will evaluate whether Vitamin D replacement at high doses will show improvement in the core symptoms of autism, including sociability, eye contact, anger outbursts, stimming behavior, and sleep.

The purpose of the study is to evaluate child and parent outcomes after participation in the treatment program JumpStart Learning-to-Learn (JSLTL). JSLTL is a new approach to early intervention for autism, best characterized as a "first intervention" consisting of an intensive, full-time week of parent and child trainings.